UNSPSC 51183308: Sitagliptin phosphate hydrate

This classification denotes a protease inhibitor and anti-diabetic agent with the molecular structure C16H15F6N5O.H2O.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, TS63EW8X6F chemically known as 1,2,4-triazolo(4,3-a)pyrazine, 7-((3r)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl)-5,6,7,8-tetrahydro-3-(trifluoromethyl), phosphate (1:1) monohydrate, but more commonly known as sitagliptin phosphate, which bears US NIH Compound Identifier 11591741.

European Medicines Agency schedules Sitagliptin phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25200. Most nations, for tariff and trade purposes, schedule sitagliptin phosphate hydrate under HS 29335990. SMILES: C1C(C(CC(C1F)F)F)C[C@H](CC(=O)N2CCN3C(NNC3C(F)(F)F)C2)N.O.OP(=O)(O)O.

UNSPSC 51183308 Sitagliptin phosphate hydrate is a Commodity code covering a specific diabetes medication active pharmaceutical ingredient supplied through state and local cooperative purchasing frameworks for distribution across participating government health systems and facilities. State and local governments procure sitagliptin phosphate hydrate and related generic pharmaceuticals primarily through multistate cooperative purchasing alliances that aggregate demand across member jurisdictions and health departments to negotiate volume pricing and standardized supply agreements with manufacturers and authorized wholesalers. The issuing bodies soliciting under this code include state departments of administration, multistate purchasing consortia like MMCAP, and subordinate state and local health systems participating in cooperative agreements. Procurement typically requires vendors to meet cGMP certification, Drug Supply Chain Security Act compliance, and FDA regulatory requirements, maintain relationships with authorized pharmaceutical wholesalers, and agree to performance metrics and administrative fee structures tied to contract compliance.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions. MMCAP requires vendors to supply sitagliptin phosphate hydrate and other identified pharmaceutical products through three authorized wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC — with awarded products available in the marketplace by May 15, 2026 and contracts effective July 1, 2026. Evaluation criteria prioritize price competitiveness at 75 percent weight, with additional scoring on fixed pricing for the contract term (10 percent), price format compliance (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). Vendors must maintain commercial general liability insurance of $5 million per occurrence, network security and privacy liability of $2 million, and professional liability of $2 million. The contract term is two years for new vendors with optional MMCAP extensions, or amendments aligned with existing agreement expirations through June 30, 2028 for incumbents.